News
- Cambridge, MA – September 14, 2023Nona Biosciences Expands Antibody Discovery Collaboration with BeiGene
- Cambridge, MA – July 13, 2023Nona Biosciences Announces Business Update of Collaboration on Antibody Drug Conjugate (ADC) with DualityBio
- CAMBRIDGE, MA— June 6, 2023Nona Biosciences Appoints Steve Arkinstall, D. Phil., as Chief Scientific Advisor
- CAMBRIDGE, MA - May 23, 2023Nona Biosciences Enters into Antibody Discovery Agreement with OPKO Health's ModeX Therapeutics
- CAMBRIDGE, MA— May 11, 2023Nona Biosciences Announces Strategic Collaboration Agreement with PharmaEssentia Innovation Research Center
- CAMBRIDGE, MA— April 18, 2023Nona Biosciences and Washington University Join Forces to Tackle Emerging RNA Viruses
- CAMBRIDGE, MA— February 10, 2023Nona Biosciences Enters into HCAb Based Antibody Discovery Collaboration Agreement with Mythic Therapeutics
- CAMBRIDGE, MA— December 9, 2022Nona Biosciences Enters into Harbour Mice® Based Drug Discovery License Agreement with Kelun Biotech
- CAMBRIDGE, MA— November 21, 2022Nona Biosciences Enters into HCAb Based Drug Discovery Collaboration Agreement with Dragonfly Therapeutics
- CAMBRIDGE, MA— November 14, 2022Nona Biosciences Announces to Attend PEGS Europe 2022